Dacarbazine is a chemotherapy medication called an alkylating agent. It's mainly used to treat Hodgkin’s lymphoma (also called Hodgkin’s disease). This medication is also approved for melanoma, a type of skin cancer. Dacarbazine doses are given at an infusion center or clinic as an injection into the vein (intravenous or IV). Possible side effects include nausea, loss of appetite, and low blood cell counts. Dacarbazine is a generic medication; the brand name DTIC-Dome is no longer available.
Hodgkin’s lymphoma, given with other anticancer medications
Metastatic melanoma (cancer that has spread)
Dacarbazine is a type of traditional chemotherapy medication that works to slow or stop the cancer from spreading. More specifically, it’s an alkylating agent.
Dacarbazine works by attaching to the cancer cell’s DNA and damaging the DNA. This usually kills the cancer cell.
Source: DailyMed
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Also, because of the way these medicines act on the body, there is a chance that they might cause other unwanted effects that may not occur until months or years after the medicine is used. These delayed effects may include certain types of cancer, such as leukemia. Discuss these possible effects with your doctor.
Check with your doctor immediately if any of the following side effects occur:
More common
Redness, pain, or swelling at place of injection
Check with your doctor as soon as possible if any of the following side effects occur:
Rare
Sores in mouth and on lips
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
This medicine may cause a temporary loss of hair in some people. After treatment with dacarbazine has ended, normal hair growth should return.
After you stop using this medicine, it may still produce some side effects that need attention. During this period of time, check with your doctor immediately if you notice the following side effects:
Black, tarry stools
blood in urine or stools
cough or hoarseness, accompanied by fever or chills
fever or chills
lower back or side pain, accompanied by fever or chills
painful or difficult urination, accompanied by fever or chills
pinpoint red spots on skin
unusual bleeding or bruising
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Is part of a recommended treatment plan for Hodgkin’s lymphoma
Often causes low blood cell counts, which can put you at risk for infections and bleeding
Commonly causes nausea
Tell the nurse right away if you feel any pain, burning, or warmth during your dacarbazine infusion. It's possible for the medication to leak from the vein and reach healthy tissue nearby, which can be painful. Your care team will try to prevent this from happening by giving you a certain type of IV access device, like a port.
Dacarbazine commonly causes nausea and vomiting. Your oncologist will prescribe antiemetics, like ondansetron (Zofran) or prochlorperazine, for you to take at home (if they haven’t already). Contact your care team if the nausea or vomiting becomes too bothersome.
Make sure you drink plenty of fluids to stay hydrated if you experience vomiting as a side effect of dacarbazine. This is also helpful if you have diarrhea, which is another possible but pretty rare side effect. Avoid sugary sports drinks though because sugar won't help replace the electrolytes you've lost and can make diarrhea worse. Talk with your care team if you need help managing these side effects.
Dacarbazine often causes you to have a low white blood cell count. This can make it hard for your body to fight infections well if you get sick. You can help prevent getting infections by washing your hands often, avoiding crowds, and washing raw fruits and vegetables thoroughly before eating them.
Check your temperature regularly, such as once a day. Call your care team as soon as possible if your temperature is 100.4 degrees Fahrenheit or higher; this means you have a fever. Sometimes, having a fever can be the only sign that you’re sick. It’s important to let your care team know if you get sick so they can help prevent any infections from getting worse.
Sometimes, dacarbazine can irritate your liver. Be sure to get any blood tests that your oncologist tells you to do during treatment. Your oncologist uses these test results to check your liver health and make sure it's safe for you to keep taking this medication. Call your care team right away if you have stomach pain, yellowish skin, or yellow around the whites of your eyes since these can be signs of liver problems.
Dacarbazine can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Dacarbazine commonly causes low blood cell counts, which can sometimes be dangerous. Low red blood cell counts can lead to problems like anemia and tiredness. And low platelet levels can put you at risk for bleeding. What's more, a low white blood cell count puts you at risk for serious and life-threatening infections because your immune system is weaker. You might be more likely to have complications from having low white blood cell counts if you’re older than 65 or if you’ve had chemotherapy or radiation before.
Your oncology care team will check your blood cell counts before every dacarbazine treatment. They'll pay closer attention to your white blood cell counts. If your counts are too low, your oncologist might make adjustments to your treatment to give your body time to make new blood cells.
Since your immune system can get weak during treatment and you're at risk for infections, it’s important to do your best to avoid getting sick. Wash your hands often and avoid crowds. Check your temperature regularly, and call your care team right away if your temperature is 100.4 degrees Fahrenheit or higher.
Rarely, some people who took dacarbazine developed liver damage, including blood clots in their liver. This mostly happened when dacarbazine was given with other chemotherapy medications.
Your oncology care team will keep track of your liver health on a regular basis to make sure dacarbazine is still safe for you to take. If your liver test results are too high, your oncologist might pause or stop your treatment with dacarbazine while they check for possible problems. Call your care team right away if you experience symptoms of liver problems, such as stomach pain, yellowish skin, or yellow around the whites of your eyes.
Based on animal studies, dacarbazine might harm an unborn baby or raise the risk for miscarriage (pregnancy loss) if it's given during pregnancy. Let your oncologist know right away if you become pregnant while you're getting treated with dacarbazine.
It’s possible to have a serious allergic reaction called anaphylaxis after you get your dacarbazine injection. Get medical attention as soon as possible if you have sudden trouble breathing, tightness in your throat or chest, an itchy rash, or sudden confusion.
Your oncologist will calculate your dose based on your body surface area (BSA; in units of m2), which takes into account your height and weight.
The dose will also vary depending on what type of cancer you have and which other medications you’re taking with dacarbazine.
Hodgkin’s lymphoma: The most common dose is 375 mg/m2 injected into the vein (IV) every 2 weeks.
Metastatic melanoma: The recommended dose is 250 mg/m2 given IV once per day for 5 days (can be repeated every 3 weeks). Another dosing option is 2 mg/kg to 4.5 mg/kg of body weight per day given IV for 10 days (can be repeated every 4 weeks).
Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.
Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
American Cancer Society. (2018). What Is Hodgkin lymphoma?
American Cancer Society (2019). How chemotherapy drugs work.
American Cancer Society. (2023). Chemotherapy for melanoma skin cancer.
American Cancer Society. (2024). Anemia (low red blood cell counts).
American Cancer Society. (2024). Fevers.
American Cancer Society. (2024). Neutropenia (low white blood cell counts).
American Cancer Society. (2024). Thrombocytopenia (low platelet count).
Bates, S. A. (2024). Deoxyribonucleic acid (DNA). National Human Genome Research Institute.
Boschi, R., et al. (2012). Extravasation of antineoplastic agents: Prevention and treatments. Pediatric Reports.
Engert, A., et al. (2010). Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. The New England Journal of Medicine.
Esposito, S., et al. (2016). Chemotherapy against cancer during pregnancy: A systematic review on neonatal outcomes. Medicine.
MedlinePlus. (2023). Low white blood cell count and cancer.
Meitheal Pharmaceuticals Inc. (2024). Dacarbazine injection, powder, for solution [package insert]. DailyMed.
National Cancer Institute. (n.d.). ABVD regimen.
National Cancer Institute. (n.d.). PET scan.
National Cancer Institute. (n.d.). Port.
National Cancer Institute. (2023). Nausea and vomiting related to cancer treatment (PDQ®)–Health professional version.
National Center for Chronic Disease Prevention and Health Promotion. (n.d.). What you need to know: Neutropenia and risk for infection.
National Comprehensive Cancer Network. (2021). Anemia and neutropenia: Low red and white blood cell counts.
National Comprehensive Cancer Network. (2022). Nausea and vomiting.
National Comprehensive Cancer Network. (2023). Hodgkin lymphoma.
National Comprehensive Cancer Network. (2024). Melanoma.
National Comprehensive Cancer Network. (2024). Soft tissue sarcoma.
Rossi, A., et al. (2017). Chemotherapy-induced alopecia management: Clinical experience and practical advice. Journal of Cosmetic Dermatology.
West, H. J. (2017). Chemotherapy-induced hair loss (alopecia). Journal of the American Medical Association Oncology.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.